ITUA20161364A1 - Inibitore di tnf alpha astrocitario per l’uso nel trattamento di malattie neurologiche. - Google Patents

Inibitore di tnf alpha astrocitario per l’uso nel trattamento di malattie neurologiche.

Info

Publication number
ITUA20161364A1
ITUA20161364A1 ITUA2016A001364A ITUA20161364A ITUA20161364A1 IT UA20161364 A1 ITUA20161364 A1 IT UA20161364A1 IT UA2016A001364 A ITUA2016A001364 A IT UA2016A001364A IT UA20161364 A ITUA20161364 A IT UA20161364A IT UA20161364 A1 ITUA20161364 A1 IT UA20161364A1
Authority
IT
Italy
Prior art keywords
astrocitary
inhibitor
treatment
neurological diseases
tnf alpha
Prior art date
Application number
ITUA2016A001364A
Other languages
English (en)
Inventor
Antonino Cattaneo
Simona Capsoni
Original Assignee
Antonino Cattaneo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antonino Cattaneo filed Critical Antonino Cattaneo
Priority to ITUA2016A001364A priority Critical patent/ITUA20161364A1/it
Priority to ES17714288T priority patent/ES2924994T3/es
Priority to DK17714288.2T priority patent/DK3423074T3/da
Priority to US16/080,714 priority patent/US20190092825A1/en
Priority to PCT/IB2017/051246 priority patent/WO2017149503A1/en
Priority to EP17714288.2A priority patent/EP3423074B1/en
Publication of ITUA20161364A1 publication Critical patent/ITUA20161364A1/it
Priority to US16/928,735 priority patent/US20200339647A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ITUA2016A001364A 2016-03-04 2016-03-04 Inibitore di tnf alpha astrocitario per l’uso nel trattamento di malattie neurologiche. ITUA20161364A1 (it)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ITUA2016A001364A ITUA20161364A1 (it) 2016-03-04 2016-03-04 Inibitore di tnf alpha astrocitario per l’uso nel trattamento di malattie neurologiche.
ES17714288T ES2924994T3 (es) 2016-03-04 2017-03-03 Inhibidor de TNF-alfa astrocitario para uso en el tratamiento de enfermedades neurológicas
DK17714288.2T DK3423074T3 (da) 2016-03-04 2017-03-03 Inhibitor af astrocyt tnf alfa til anvendelse til behandling af neurologiske sygdomme
US16/080,714 US20190092825A1 (en) 2016-03-04 2017-03-03 Inhibitor of astrocyte tnf alpha for use in the treatment of neurological diseases
PCT/IB2017/051246 WO2017149503A1 (en) 2016-03-04 2017-03-03 Inhibitor of astrocyte tnf alpha for use in the treatment of neurological diseases
EP17714288.2A EP3423074B1 (en) 2016-03-04 2017-03-03 Inhibitor of astrocyte tnf alpha for use in the treatment of neurological diseases
US16/928,735 US20200339647A1 (en) 2016-03-04 2020-07-14 Inhibitor of astrocyte tnf alpha for use in the treatment of neurological diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUA2016A001364A ITUA20161364A1 (it) 2016-03-04 2016-03-04 Inibitore di tnf alpha astrocitario per l’uso nel trattamento di malattie neurologiche.

Publications (1)

Publication Number Publication Date
ITUA20161364A1 true ITUA20161364A1 (it) 2017-09-04

Family

ID=56507644

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUA2016A001364A ITUA20161364A1 (it) 2016-03-04 2016-03-04 Inibitore di tnf alpha astrocitario per l’uso nel trattamento di malattie neurologiche.

Country Status (6)

Country Link
US (2) US20190092825A1 (it)
EP (1) EP3423074B1 (it)
DK (1) DK3423074T3 (it)
ES (1) ES2924994T3 (it)
IT (1) ITUA20161364A1 (it)
WO (1) WO2017149503A1 (it)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006893A1 (en) * 2006-07-13 2008-01-17 Lay Line Genomics S.P.A. Muteins of hngf, therapeutic uses and pharmaceutical compositions
WO2012170452A2 (en) * 2011-06-06 2012-12-13 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0617823A2 (pt) 2005-10-31 2011-08-09 Laboratoires Serono Sa uso de sdf-1 para o tratamento e/ou prevenção de doenças neurológicas e composição farmacêutica

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006893A1 (en) * 2006-07-13 2008-01-17 Lay Line Genomics S.P.A. Muteins of hngf, therapeutic uses and pharmaceutical compositions
WO2012170452A2 (en) * 2011-06-06 2012-12-13 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRANCESCA MALERBA ET AL: "Functional Characterization of Human ProNGF and NGF Mutants: Identification of NGF P61SR100E as a "Painless" Lead Investigational Candidate for Therapeutic Applications", PLOS ONE, vol. 10, no. 9, 15 September 2015 (2015-09-15), pages e0136425, XP055310595, DOI: 10.1371/journal.pone.0136425 *
SIMONA CAPSONI ET AL: "Intranasal "painless" Human Nerve Growth Factors Slows Amyloid Neurodegeneration and Prevents Memory Deficits in App X PS1 Mice", PLOS ONE, vol. 7, no. 5, 30 May 2012 (2012-05-30), pages e37555, XP055310608, DOI: 10.1371/journal.pone.0037555 *

Also Published As

Publication number Publication date
EP3423074A1 (en) 2019-01-09
EP3423074B1 (en) 2022-04-13
ES2924994T3 (es) 2022-10-13
US20200339647A1 (en) 2020-10-29
US20190092825A1 (en) 2019-03-28
WO2017149503A1 (en) 2017-09-08
DK3423074T3 (da) 2022-07-18

Similar Documents

Publication Publication Date Title
IL282663A (en) Bt1718 for use in treating cancer
PL3429571T3 (pl) Kombinacje inhibitorów lsd1 do zastosowania w leczeniu chorób nowotworowych
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
DK3806898T3 (da) Gremlin-1-antagonist til anvendelse i behandling af cancer
PL3485890T3 (pl) Inhibitory SGLT2 do leczenia zaburzeń metabolicznych u zwierząt psowatych
IT201700072994A1 (it) Sistema plurisensoriale adattato per la prevenzione di malattie professionali nell’ambiente di lavoro, e metodo per l’uso del sistema
PL3490560T3 (pl) Niraparyb do stosowania w sposobie leczenia nowotworu prostaty
PL3592355T3 (pl) Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego
HUE053927T2 (hu) Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra
IL256000A (en) Quantifying her 2 protein for optimal cancer therapy
EP3370725A4 (en) PEDIATRIC DOSAGE FOR THE TREATMENT OF CANCER WITH AN EZH2 INHIBITOR
IT201600101413A1 (it) Composizione liquida per uso nel trattamento del reflusso gastroesofageo
DK3463436T3 (da) Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling
IT201700025666A1 (it) Composizione per l’uso nel trattamento dell’ipercolesterolemia e nella prevenzione di patologie cardiovascolari.
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
CY2024037I2 (el) Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων
IL282313A (en) Abituzumab for the treatment of colorectal cancer
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
HUE056798T2 (hu) Imatinib stroke kezelésében való alkalmazásra
IT201700111939A1 (it) Composizione farmaceutica per l’uso nel trattamento di stati infiammatori
IL258340A (en) Quantifying met protein for cancer treatment
HUE058645T2 (hu) Gyógyszer köszvény kezelésében való felhasználásra